Phorum

Drug Substance

Delivering globally on in-line monitoring and real-time release

BioPhorum is increasing its focus on delivering against strategic goals of member companies as outlined in the BioPhorum Biomanufacturing Technology Roadmap. The first step in achieving this is to form a team with a cross-Phorum focus to implement these technologies – the ILM/RTR Adoption team. The team will look at the ongoing work and opportunities to collaborate on environmental, organizational and technical factors that can be most readily addressed at industry level.

The BioPhorum Biomanufacturing Technology Roadmap (The Roadmap) set a broad vision for the future of biomanufacturing to catalyze industry action. It identified the market trends that are exerting massive pressure on the industry to evolve and deliver a step change in performance and cost reduction.

 

In-line monitoring and real-time release

The Roadmap highlighted that in-line monitoring and real-time release (ILM/RTR) has a crucial contribution to make in this change.

Currently across our industry 60-70% of process testing and environmental monitoring of bulk drug substance and drug product is performed either at-line or off-line; requiring significant amounts of non-value adding work, sample collection, labeling, transport to the QC laboratory, sample receipt and logging, sample testing and communication of results. The entire process is inefficient.

Implementing in-line, real-time monitoring for bioprocesses presents both a unique opportunity and bewildering challenge given the complexity of bioprocesses, the variability of raw materials, and living organisms, plus the need to do it in single-use equipment and in facilities shifting from batch to continuous processing.

A successful implementation in a fully automated facility will need robust, reliable, low-cost and easy-to-maintain in-line probes.

Next steps

The Roadmap has gained significant credibility in the industry and has initiated a number of successful technology development projects. As a result, it is increasingly being seen by leaders as an indispensable vehicle for making the future happen.  After consulting all of the BioPhorum Drug Substance member companies, and confirming this with a range of other sponsors ILM/RTR was chosen as the first cross- Phorum initiative with a mandate to make adoption into day to day operations a reality.

ILM/RTR has the following goals:

  • Speed: a reduction in the time to release a product from 4–6 weeks to 1–2 days
  • Cost: a 90% reduction in inventory quantity
  • Quality: a reduction in the cost of non-quality to 2% of total operational costs.

The team has already identified the attributes that are the most critical in realizing these goals to biomanufacturers, key suppliers and academic researchers.

The ILM/RTR Adoption team is now being recruited and around 15 companies are already providing resources for the project.

Dave Connolly, Head of Manufacturing Science & Technology at Takeda commented, “Working with BioPhorum on this topic provides an exciting opportunity to deliver on the industry’s In-line Monitoring and Real-time Release ambitions. Working in concert with key stakeholders across other leading biopharma companies ensures that we maximize the return on our individual efforts and crucially enables us to make real change at the industry level.”

There is a huge amount of work ahead to achieve the vision set out in the Roadmap and meet the challenges of delivering successful ILM/RTR. But with your help, we can achieve great things.

For more information about the ILM/RTR project, contact Derek Willison-Parry through info@biophorum.com.

Contact address

BioPhorum
The Gridiron Building
One Pancras Square
London
N1C 4AG

Newsletter subscribe

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.



© 2019 Biophorum Operations Group · All Rights Reserved

Registered Address: 5 Westbrook Court · 2 Sharrow Vale Road · Sheffield · S11 8YZ

Company Number 06794795 · VAT Number GB298617544

Driving progress in Cell & Gene Therapy

Now with 19 member companies and 183 subject matter experts, the BioPhorum Cell & Gene Therapy (C>) Phorum has made great strides since its formation[...]

Read More
Cell and Gene Therapy Phorum accelerates progress

The BioPhorum Cell & Gene Therapy Phorum has made significant progress since its creation in 2018 – from building networks and sharing knowledge to endorsing[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Sharing powerful collaboration data on the impact of resin cycling on viral clearance

A crucial issue for biotechnology products is that the mammalian cell lines commonly used in manufacturing are susceptible to viral contamination. Therefore, demonstration of viral[...]

Read More
Industry bioassay approach helps to shape the future

In 2018, members of the Development Group Bioassay workstream came together to write a best practices paper on bioassay development. We are delighted to announce[...]

Read More
Sharing ideas on forced degradation

“Forced degradation studies are an important part of the drug lifecycle process as they can inform many aspects of drug development,” said Jennifer Halley, Principal[...]

Read More
Delivering globally on in-line monitoring and real-time release

BioPhorum is increasing its focus on delivering against strategic goals of member companies as outlined in the BioPhorum Biomanufacturing Technology Roadmap. The first step in[...]

Read More
New and improved User Requirements Toolkit for single-use systems

To help customers and manufacturers achieve a ‘right first time’ implementation of single-use systems, BioPhorum launched a User Requirements Toolkit in June 2018. This includes[...]

Read More
Why raw materials are the unsung heroes of human medicinal product manufacturing

“It’s not easy being a biopharmaceutical raw material…” So says Kara Stockett Quinn of Merck & Co. In a recent American Pharmaceutical Review article, Quinn[...]

Read More
PUPSIT – An update on BioPhorum/PDA work to develop a risk-based position
Read More
Driving the evolution of secondary packaging

How do we transition from large-batch manufacture to small-batch, high-value packaging runs?

Read More
Hi-tech ambitions for Fill Finish

The Fill Finish Phorum has recently embarked on a series of exciting and ambitious initiatives, exploring new technologies and processes to enhance the efficiency and[...]

Read More
Logistics collaboration hub: An opportunity for significant time and cost savings

Most biopharmaceutical manufacturers use a network of logistics service providers (LSPs) to deliver warehousing, transport and distribution services, and they are usually linked using customized,[...]

Read More
The ‘how to’ guide to implementing Agile in GxP

The publication of the Guidance on the use of Agile in a GxP Environment document in 2017 was well received.It described how the use of[...]

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
BioPhorum’s Maturity Assessment Tool gains momentum
Read More
Supply chain, forecasting and demand planning solutions gain momentum

The relationship between suppliers and manufacturers is one of the most crucial in biopharmaceutical manufacturing. This is especially the case when forecasting and supply planning.[...]

Read More
2018 highlights

BioPhorum’s mission has always been to make the journey for tackling industry challenges better, faster and cheaper for members. By helping you to work on[...]

Read More
Delivering globally on in-line monitoring and real-time release

BioPhorum is increasing its focus on delivering against strategic goals of member companies as outlined in the BioPhorum Biomanufacturing Technology Roadmap. The first step in[...]

Read More
Removing the roadblocks to continuous biomanufacturing

Continuous downstream processing is increasingly seen as a feasible approach for manufacturing biologics. The industry recognises that it offers advantages over batch-based processing by:

Read More
Changing mindsets with a modular approach

Historically, manufacturers have used a ‘waterfall’ approach when designing and building their production facilities, sequentially resolving and specifying all aspects up front and in detail[...]

Read More
Slicing years off change implementation

As the first regulatory authority in Latin America to gain full membership of the International Council for Harmonization (ICH), the Brazilian Health Regulatory Agency (Anvisa)[...]

Read More
BioPhorum Regulatory Interaction: helping to open doors

To implement any change in the biopharmaceutical manufacturing industry it is important to engage with and collaborate with the regulators. Set up two years ago,[...]

Read More
Regulatory compliance: what lessons can be learned?

BioPhorum delivery of value from the disposables five-year plan - supplier change notifications for single-use systems

Read More
Navigating the maze of medical technology regulation: a solo voyage or a team effort?

Medical technology is a global business, generating annual revenues of over $400bn. The sector encompasses a broad range of technologies: from in-vitro diagnostics and diagnostic[...]

Read More

IaaS Cloud webinar recording play back
Read More
New BPIT guidance to align cloud services to regulatory requirements
Read More
Data Integrity and Agile Webinars to support industry response to regulators
Read More
How to validate informatics in CPV programs

The BioPhorum Continued Process Verification (CPV) and Informatics team has published a paper to support a risk-based approach for the validation of informatics systems for[...]

Read More
Continued Process Verification delivering real saving in time and money

More than 50 per cent of biopharma products on the market now have Continued Process Verification (CPV) plans in place.  Thanks to the CPV white[...]

Read More
A roadmap for the implementation of continued process verification

This article provides a roadmap draws on the content of the CPV case study to provide a step-by-step guide in a more accessible form.

Read More
How smart is your maintenance?

Faster. Cheaper. Smarter. All companies are under pressure to achieve more with less, not least with their maintenance programs. But while ‘faster’ and ‘cheaper’ maintenance[...]

Read More
Digital plant maturity model webinar replay
Read More
Digital Plant Maturity Model workstream to host webinar
Read More
New guidance available on Forecasting and Demand Planning to streamline supply chain performance
Read More
Changes to BioPhorum extractables protocol

The BioPhorum Extractables team has shown the benefits of great collaboration between biomanufacturers and suppliers – they agreed to significantly reduce extractables testing for single use[...]

Read More
Host cell proteins poster

This poster presented at the BEBPA Conference, San Francisco builds and consolidates the information currently available in the industry for assessing process risk from Host[...]

Read More
Host cell protein risk assessment, an industry approach

Host cell protein (HCP) constitutes a significant class of process-related impurities in biological drugs.

Read More
BEBPA risk assessment workshop
Read More
New and improved User Requirements Toolkit for single-use systems

To help customers and manufacturers achieve a ‘right first time’ implementation of single-use systems, BioPhorum launched a User Requirements Toolkit in June 2018. This includes[...]

Read More
What is BioPhorum and how does it work
Read More
Overview of the BioPhorum Technology Roadmap
Read More
Japan’s bioeconomy strategy objectives and principles
Read More